Literature DB >> 11248785

Glycoprotein IIb/IIIa Inhibition as an adjunct to rescue angioplasty after failed fibrinolysis.

J A Sallach1, A B Greenbaum.   

Abstract

Mesh：

Substances：

Year:  2001        PMID： 11248785     DOI： 10.1023/a:1008975224306

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN： 0929-5305            Impact factor:   2.300


× No keyword cloud information.
  14 in total

Review 1.  The pathogenesis of coronary artery disease and the acute coronary syndromes (2).

Authors:  V Fuster; L Badimon; J J Badimon; J H Chesebro
Journal:  N Engl J Med       Date:  1992-01-30       Impact factor: 91.245

2.  Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.

Authors: 
Journal:  N Engl J Med       Date:  1997-06-12       Impact factor: 91.245

3.  Incidence of bleeding complications associated with abciximab use in conjunction with thrombolytic therapy in patients requiring percutaneous transluminal coronary angioplasty.

Authors:  D W Sundlof; P Rerkpattanapitat; N Wongpraparut; P Pathi; M N Kotler; L E Jacobs; G S Ledley; S Yazdanfar
Journal:  Am J Cardiol       Date:  1999-06-01       Impact factor: 2.778

4.  Effectiveness of early coronary angioplasty and abciximab for failed thrombolysis (reteplase or alteplase) during acute myocardial infarction (results from the GUSTO-III trial). Global Use of Strategies To Open occluded coronary arteries.

Authors:  J M Miller; R Smalling; E M Ohman; C Bode; A Betriu; N S Kleiman; J S Schildcrout; E Bastos; E J Topol; R M Califf
Journal:  Am J Cardiol       Date:  1999-10-01       Impact factor: 2.778

5.  Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators.

Authors:  S J Brener; L A Barr; J E Burchenal; S Katz; B S George; A A Jones; E D Cohen; P C Gainey; H J White; H B Cheek; J W Moses; D J Moliterno; M B Effron; E J Topol
Journal:  Circulation       Date:  1998-08-25       Impact factor: 29.690

6.  Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. EPIC investigators.

Authors:  J Lefkovits; R J Ivanhoe; R M Califf; B A Bergelson; K M Anderson; G L Stoner; H F Weisman; E J Topol
Journal:  Am J Cardiol       Date:  1996-05-15       Impact factor: 2.778

7.  The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction.

Authors: 
Journal:  N Engl J Med       Date:  1993-11-25       Impact factor: 91.245

8.  Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study.

Authors:  N S Kleiman; E M Ohman; R M Califf; B S George; D Kereiakes; F V Aguirre; H Weisman; T Schaible; E J Topol
Journal:  J Am Coll Cardiol       Date:  1993-08       Impact factor: 24.094

9.  A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group.

Authors:  C L Grines; K F Browne; J Marco; D Rothbaum; G W Stone; J O'Keefe; P Overlie; B Donohue; N Chelliah; G C Timmis
Journal:  N Engl J Med       Date:  1993-03-11       Impact factor: 91.245

10.  Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) trial.

Authors: 
Journal:  J Am Coll Cardiol       Date:  1998-12       Impact factor: 24.094
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.